Nomura forecasts strong growth and synergy realization for Torrent Pharmaceuticals
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Nomura expects Torrent Pharmaceuticals to report strong second-quarter results for FY27. The company recorded 16.3% year-on-year growth in the Indian pharmaceutical market in the July-September quarter, which exceeded the broader market growth of 12% after consolidating JB Pharma. The brokerage also expects further EBITDA margin expansion as cost synergies from the JB Pharma acquisition continue to materialize.
From moneycontrol.com
Why it matters
The growth in the Indian market and the realization of cost synergies from the acquisition of JB Pharma are expected to boost Torrent Pharmaceuticals' profitability. Nomura forecasts 17% year-on-year constant-currency growth for the second quarter.
From moneycontrol.com
Who's involved
- NomuraProvides financial ratings and forecasts for Torrent Pharmaceuticals.
- Torrent PharmaceuticalsAcquired a controlling stake in JB Pharma and is reporting growth in the Indian market.
- JB PharmaWas acquired by Torrent Pharmaceuticals, contributing to cost synergies.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- JB PharmaSpeculative
JB Pharma might see improved gross margins and overhead cost savings as cost synergies from the acquisition continue to materialize.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Torrent's growth and acquisition synergies increase competition for Laurus LabsTorrent's strong growth and synergies increase competition for Laurus LabsLikely
- Torrent Pharmaceuticals' growth may boost export opportunities in AfricaTorrent Pharmaceuticals' growth may boost export opportunities in AfricaPossible
- Torrent Pharma's stock correction may affect Mumbai market activityTorrent Pharma's stock correction may influence market sentiment in MumbaiPossible
Keep exploring
The entities involved
-
Nomura
corporation in Japan
-
Torrent Pharmaceuticals
Indian multinational pharmaceutical company
Nothing else this week.
-
JB Pharma
company in the Czech Republic
Nothing else this week.
Related events
- Nomura rated Torrent Pharmaceuticals 'Neutral' and highlighted strong growth in the Indian Pharmaceutical Market.
- Nomura retained a buy rating, Morgan Stanley retained equal-weight, and CLSA downgraded Godrej Consumer Products stock.
- Nomura retained a Buy rating for Gland Pharma Ltd, citing its pivot to a CDMO model.
- Nomura upgraded the stock rating for Toto Ltd. on September 4, 2026.
- Nomura projected strong June quarter for the hospitality sector, forecasting growth for ITC Hotels and Chalet.